Articles tagged "Pediatric"

2017 American Transplant Congress
Use of Biodegradable Stents for the Treatment of Anastomotic Biliary Strictures in Pediatric Liver Transplant Patients.
J. Quintero,¹ J. Juamperez,¹ V. Cabello,¹ M. Perez,³ I. Bilbao,² J. Molino,¹ R. Charco.²
¹Pediatric Liver Transplant Unit, Hospital Vall d'Hebron, Barcelona, Catalunya, Spain; ²HPB Surgery and Transplants Department, Hospital Vall d'Hebron, Barcelona, Catalunya, Spain; ³Interventional Radiologist Department, Hospital de La Vall d'Hebron, Barcelona, Catalunya, Spain
Objectives To evaluate feasibility, safety and mid-time outcome of pediatric liver transplant patients treated with a biodegradable biliary stent for anastomotic biliary strictures.Methods Retrospective study…
2017 American Transplant Congress
Refinement of an Old Faithful: A Standardized Flow Cytometry Approach to Measure Donor-Recipient Alloreactivity (a Pilot Study).
A. Halpin,¹ M. Sosniuk,¹ S. Urschel,¹ P. Campbell,² I. Larsen,¹ L. West.¹
¹Pediatrics, Alberta Transplant Institute, Canadian National Transplant Reseach Program, University of Alberta, Edmonton, Canada; ²Lab Medicine and Pathology, University of Alberta, Edmonton, Canada
Purpose: Donor-specific antibody (DSA) and antibody (Ab)-mediated rejection are challenges in long-term outcomes and limit re-transplantation. Sensitizing events such as homografts in surgical procedures, assist…
2017 American Transplant Congress
Rabbit Anti-Human Thymocyte Immunoglobulin (rATG) for Rescue Treatment of Chronic Antibody-Mediated Rejection (cAMR) After Pediatric Kidney Transplantation.
L. Pape, T. Ahlenstiel-Grunow, J. Drube, M. Kreuzer, C. Lerch, N. Kanzelmeyer, S. Wente, I. Hennies, Y. Cihan.
Pediatric Nephrology, Hannover Medical School, Hannover, Germany
Background. Chronic antibody-mediated rejection (cAMR) is the leading cause of long-term graft loss after kidney transplantation. Treatment guidelines include rituximab, immunoadsorption, immunoglobulins and/or bortezomib, but…
2017 American Transplant Congress
Reassessing Thymoglobulin Induction in Kidney Transplantation (RETHINK): An Analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry.
I. Ashoor,¹ K. Martz,² R. Beyl,³ V. Dharnidharka.⁴
¹Children's Hospital, New Orleans, LA; ²EMMES Corporation, Rockville, MD; ³Pennington Biomedical Research Center, Baton Rouge, LA; ⁴Washington University, St. Louis, MO
There is no consensus on Thymoglobulin (TMG) dose used for induction immunosuppression (IS) in pediatric kidney transplants (KTx). We aimed to identify: 1) TMG induction…
2017 American Transplant Congress
Comparing Outcomes Between Technical Variant Liver Allografts and Whole Allografts in Pediatric Liver Transplantation: A Single Center's Experience.
A. Gallo,¹ J. Lee,¹ M. Damian,² D. Stoltz,¹ C. Bonham,¹ C. Esquivel,¹ J. Mendoza.³
¹Surgery, Stanford University, Palo Alto, CA; ²Intensive Care, Stanford University, Palo Alto, CA; ³Anesthesia, Stanford University, Palo Alto, CA
Objective: To compare the outcome of technical variant liver transplants to whole allograft liver transplants in pediatric recipients.Methods: A single center retrospective analysis of outcomes…
2017 American Transplant Congress
Cyclosporine Effects on Blood Pressure Are Exaggerated in Pubertal Girls After Renal Transplantation.
A. Melk,¹ R. Sugianto,¹ B. Schmidt,² K. Krupka,³ B. Höcker,³ B. Tönshoff,³ E. Wühl.³
¹Pediatric Nephrology, Hannover Medical School, Hanover, Germany; ²Nephrology, Hannover Medical School, Hanover, Germany; ³Pediatric Nephrology, University of Heidelberg, Heidelberg, Germany
Hypertension is a common problem after renal transplantation. We investigated potential contributing factors for high blood pressure (BP) in 336 pediatric transplant recipients from the…
2017 American Transplant Congress
Outcomes for Plasma Cell Rich Rejection in Pediatric Kidney Transplant Patients.
O. Moussa, S. Self, K. Twombley.
Medical University of South Carolina, Charleston
Introduction and Objective:Plasma cell rich rejection (PCR) has historically been associated with poor outcomes, but there has been minimal data published to date on pediatric…
2017 American Transplant Congress
Redefining Pediatric Heart Status 1A and 1B Criteria: Results of Early Policy Evaluation.
W. Cherikh,¹ R. Davies,² Y. Cheng,¹ W. Mahle.³
¹United Network for Organ Sharing, Richmond, VA; ²Alfred I duPont Hosp. for Children, Wilmington, DE; ³Children's Healthcare of Atlanta, Atlanta, GA
Background. On March 22, 2016, changes to the definitions of pediatric Status 1A and 1 B criteria were implemented in the US. These changes were…
2017 American Transplant Congress
Donor-Derived Cell-Free DNA Predicts Biopsy-Proven Acute Cellular Rejection in Pediatric Kidney Transplant Recipients.
D. Stoltz,¹ A. Brubaker,¹ M. Grskovic,² R. Woodward,² A. Gallo.¹
¹Surgery, Stanford University, Palo Alto, CA; ²CareDx, Brisbane, CA
Introduction: Surveillance of allograft health is a critical component of post-kidney transplant care. Invasive protocol biopsies are associated with secondary complications and often provide results…
2017 American Transplant Congress
Biliary Complications in Pediatric Liver Transplantation for Cystic Fibrosis: A Single-Center Experience with Choledochocholedochostomy.
P. Rizk, J. Moffett, M. Vu, R. Ackah, R. Sigireddi, M. Finegold, C. O'Mahony, A. Rana, J. Goss.
Baylor College of Medicine, Houston, TX
BackgroundFor adult liver transplants, choledochocholedochostomy or “duct-to-duct” biliary reconstruction is the standard of care. In contrast to a Roux-en-Y reconstruction, it maintains physiologic bile flow,…